Inhibition of CHK1 (Checkpoint Kinase 1) Elicits Therapeutic Effects in Pulmonary Arterial Hypertension.

Conclusions- Our results show that CHK1 exerts a proproliferative function in PAH-PASMCs by mitigating DNA damage and suggest that CHK1 inhibition may, therefore, represent an attractive therapeutic option for patients with PAH.
PMID: 31092016 [PubMed - as supplied by publisher]

Source: Arteriosclerosis, Thrombosis and Vascular Biology - May 15, 2019 Category: Cardiology Authors: Bourgeois A, Bonnet S, Breuils-Bonnet S, Habbout K, Paradis R, Tremblay E, Lampron MC, Orcholski ME, Potus F, Bertero T, Peterlini T, Chan SY, Norris KA, Paulin R, Provencher S, Boucherat O Tags: Arterioscler Thromb Vasc Biol Source Type: research